Therefore, Sirt1 agonists and bromodomain inhibitors may emerge as therapeutic strategies for diabetic nephropathy and could potentially offer new treatment directions for other organ damage caused by diabetes (Zhong et al., 2018). This evidence concerns the gene SIRT1 and diabetic kidney disease.